Koelis and Bot Image Partner to Enhance Prostate Cancer Detection with AI-Powered Fusion Biopsy Technology
核心洞察
Koelis has announced a strategic partnership with Bot Image (搜索) to integrate ProstatID (搜索)™, an FDA-cleared AI-based lesion detection software, with their Trinity (搜索)® MRI-fusion guidance system for improved prostate cancer (搜索) diagnostics.
The combined technology offers unprecedented 93.6% sensitivity-specificity (AUROC) for prostate cancer (搜索) detection, with automated 3D contouring and segmentation that significantly enhances workflow efficiency for radiologists and urologists.
Clinicians report that the integration creates a comprehensive solution that saves time and increases confidence in fusion biopsy planning, potentially advancing the standard of care for prostate cancer (搜索) diagnosis.
Koelis, a leader in prostate care innovation, has announced a new partnership with Bot Image (搜索) to enhance prostate cancer (搜索) detection capabilities through advanced AI-powered fusion biopsy technology. The collaboration, revealed at the American Urological Association (AUA) 2025 conference, combines Koelis' Trinity (搜索)® MRI-fusion guidance system with Bot Image's ProstatID (搜索)™ software to address growing demands in the U.S. prostate fusion biopsy market.
The partnership integrates ProstatID (搜索)™, the first FDA-cleared software for prostate cancer (搜索) screening and diagnosis using fully automated AI-based lesion detection, with Koelis' proprietary guidance technology. This integration aims to significantly improve both diagnostic accuracy and clinical workflow efficiency.
Advanced AI Integration Enhances Diagnostic Precision
The combined solution leverages ProstatID (搜索)™'s automated lesion detection and prostate segmentation capabilities to streamline radiologist workflow while providing processed MRI data directly to the Koelis Trinity (搜索)® system. This integration enables urologists to create detailed 3D patient-specific prostate maps that can guide both biopsy procedures and focal treatment interventions.
Dr. Jamil Syed from Cleveland Clinic Indian River Hospital's Rosner Family Health & Well Center in Vero Beach, Florida, described the combination as "a game changer" for urologists. "The automatic MRI-based lesion detection and prostate segmentation saves me time and adds confidence to my fusion biopsy plan," Dr. Syed noted.
The technology's diagnostic capabilities are particularly impressive. According to Dr. Randall Jones, CEO and founder of Bot Image (搜索), "The 93.6% sensitivity-specificity of ProstatID (搜索)™ (AUROC) is unmatched by any other software product." Unlike other AI solutions that merely assist physicians in identifying suspicious lesions, ProstatID™ performs comprehensive segmentation and classification, providing physicians with PI-RADS or Level-of-Suspicion scores and risk assessment for each lesion on a continuous scale from 1-99.
Technical Advantages and Clinical Implementation
The Koelis Trinity (搜索)® system offers several technical advantages beyond its diagnostic accuracy. As a compact system, it operates independently without requiring interfaces with external ultrasound equipment or sensors, making it a practical solution for various clinical settings.
Koelis is demonstrating this integrated technology through live, interactive demonstrations at AUA 2025 at booth #1259 from April 25th to 28th, allowing urologists and other healthcare professionals to experience the system firsthand.
Advancing Minimally Invasive Treatment Options
Beyond improving diagnostic capabilities, this partnership aligns with Koelis' broader commitment to advancing minimally invasive prostate cancer (搜索) treatments. The company has been actively involved in multi-center clinical registries in Europe and Asia focused on Trinity (搜索)-guided microwave ablation technology, offering alternatives to traditional total organ treatments such as surgical prostatectomy and radiation.
Headquartered in Grenoble, France, Koelis has pioneered MRI-US fusion image guidance technology since 2006. Their proprietary 3D ultrasound and prostate motion tracking software (OBT Fusion®) has established the company as an innovator in the field. With offices in Grenoble, Princeton (NJ, USA), Saarbrücken (Germany), and Singapore, Koelis serves patients in more than 50 countries.
Bot Image (搜索), based in Nebraska and Maine, has focused on blending AI with diagnostic and image-guided technologies since its founding in 2018. Their ProstatID (搜索)™ software received FDA clearance in 2022 and was first previewed at AUA 2024 in San Antonio, Texas.
Implications for Prostate Cancer Care
Prostate cancer (搜索) remains one of the most common cancers affecting men worldwide, with early and accurate detection being crucial for successful treatment outcomes. The integration of advanced AI capabilities with precise imaging guidance represents a significant step forward in addressing the challenges of prostate cancer diagnosis.
By improving the accuracy of lesion detection and biopsy guidance while simultaneously enhancing workflow efficiency, this partnership between Koelis and Bot Image (搜索) has the potential to improve clinical outcomes and patient care in prostate cancer (搜索) management.